Case report: Relapsing cutaneous leishmaniasis in a patient with ankylosing spondylitis treated with infliximab

American Journal of Tropical Medicine and Hygiene

Volumn 81, Issue 1, 2009, Pages 52-54

  Mueller, Matthias C ^a   Fleischmann, Erna ^b   Grunke, Mathias ^a   Schewe, Stefan ^a   Bogner, Johannes R ^a   Löscher, Thomas ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Department of Infectious Diseases and Tropical Medicine Munich ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; IMMUNOGLOBULIN G ANTIBODY; INFLIXIMAB; MILTEFOSINE; PROTOZOAL DNA; STIBOGLUCONATE SODIUM; INDUCIBLE NITRIC OXIDE SYNTHASE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AMASTIGOTE; ANKYLOSING SPONDYLITIS; ANTIBODY SPECIFICITY; ARTICLE; CASE REPORT; DISEASE COURSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; KNEE; LEISHMANIA INFANTUM; MALE; NONHUMAN; OPPORTUNISTIC INFECTION; POLYMERASE CHAIN REACTION; RECURRENT DISEASE; REMISSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SKIN BIOPSY; SKIN LEISHMANIASIS; SKIN ULCER; TREATMENT DURATION; TREATMENT OUTCOME; WOUND HEALING; DRUG ANTAGONISM; PHYSIOLOGY;

LEISHMANIA INFANTUM;

ADULT; ANTIBODIES, MONOCLONAL; HUMANS; LEISHMANIASIS, CUTANEOUS; MALE; NITRIC OXIDE SYNTHASE TYPE II; RECURRENCE; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67650284525     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2009.81.52     Document Type: Article

References (17)

1. Furst DE, Keystone EC, Kirkham B, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Burmester GR, Braun J, Emery P, Winthrop K, Bresnihan B, De Benedetti F, Dörner T, Gibofsky A, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH, 2007. Updated consensus Statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 66 (Suppl 3): iii2-iii22.
2. Romaní-Costa V, Sánchez C, Moyá F, Estany C, 2004. Visceral leishmaniasis related to infliximab administration. Enferm Infecc Microbiol Clin 22: 310.
3. Fabre S, Gibert C, Lechiche C, Dereure J, Jorgensen C, Sany J, 2005. Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with infliximab. Clin Exp Rheumatol 23: 891-892.
4. Bagalas V, Kioumis I, Argyropoulou P, Patakas D, 2007. Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept. Clin Rheumatol 26: 1344-1345.
5. Schönian G, Nasereddin A, Dinse N, Schweynoch C, Schallig HD, Presber W, Jaffe CL, 2003. PCR diagnosis and characterization of Leishmania in local and imported clinical samples. Diagn Microbiol Infect Dis 47: 349-358.
6. Pratlong F, Rioux JA, Marty P, Faraut-Gambarelli F, Dereure J, Lanotte G, Dedet JP, 2004. Isoenzymatic analysis of 712 strains of Leishmania infantum in the south of France and relationship of enzymatic polymorphism to clinical and epidemiological features. J Clin Microbiol 42: 4077-4082.
7. Mary C, Lamouroux D, Dunan S, Quilici M, 1992. Western blot analysis of antibodies to Leishmania infantum antigens: potential of the 14-kD and 16-kD antigens for diagnosis and epidemiologic purposes. Am J Trop Med Hyg 47: 764-771.
8. World Health Organization, Leishmaniasis. Available at: www.who.int/leishmaniasis/en/. Accessed November 1, 2008.
9. Dujardin JC, Campino L, Cañavate C, Dedet JP, Gradoni L, Soteriadou K, Mazeris A, Ozbel Y, Boelaert M, 2008. Spread of vector-borne diseases and neglect of leishmaniasis, Europe. Emerg Infect Dis 14: 1013-1018.
10. Bogdan C, Schönian G, Bañuls AL, Hide M, Pratlong F, Lorenz E, Röllinghoff M, Mertens R, 2001. Visceral leishmaniasis in a German child who had never entered a known endemic area: case report and review of the literature. Clin Infect Dis 32: 302-306.
11. Kuhls K, Chicharro C, Cañavate C, Cortes S, Campino L, Haralambous C, Soteriadou K, Pratlong F, Dedet JP, Mauricio I, Miles M, Schaar M, Ochsenreither S, Radtke OA, Schönian G, 2008. Differentiation and gene flow among European populations of Leishmania infantum MON-1. PLoS Negl Trop Dis 2: e261.
12. Liese J, Schleicher U, Bogdan C,2008.The innate immune response against Leishmania parasites. Immunobiology 213: 377-387.
13. Winthrop KL, 2006. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2: 602-610.
14. Fonseca SG, Romão PR, Figueiredo F, Morais RH, Lima HC, Ferreira SH, Cunha FQ, 2003. TNF-alpha mediates the induction of nitric oxide synthase in macrophages but not in neutrophils in experimental cutaneous leishmaniasis. Eur J Immunol 33: 2297-2306.
15. Kaye PM, Svensson M, Ato M, Maroof A, Polley R, Stager S, Zubairi S, Engwerda CR, 2004. The immunopathology of experimental visceral leishmaniasis. Immunol Rev 201: 239-253.
16. Murray HW, Jungbluth A, Ritter E, Montelibano C, Marino MW, 2000. Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect Immun 68: 6289-6293.
17. Tumang MC, Keogh C, Moldawer LL, Helfgott DC, Teitelbaum R, Hariprashad J, Murray HW, 1994. Role and effect of TNF-alpha in experimental visceral leishmaniasis. J Immunol 153: 768-775.